Ann: Notice of Extraordinary General Meeting/Proxy Form, page-243

Hopper raising at RAD. This time it looks a bit more positive.

Diagnostics specialist Lantheus, capitalised at $8 billion on the Nasdaq, likes the look of Aussie Radiopharm Theranostics.
Street Talk understands Lantheus has agreed to pay a 47 per cent premium to Radiopharm’s last close to come in as a cornerstone investor on an equity raise of up to $65 million. It will tip in $US7 million at 5¢ a share, with the option to top up by another $US5 million.


If he could secure a similar investment here with less dilution it would improve CHM's image a lot. An US Pharma giant investing, that's what the market needs as a reassurance.

GLTA